Borregaard ASA (OSL:BRG)
Norway
· Delayed Price · Currency is NOK | Market Cap | 16.61B |
| Revenue (ttm) | 7.71B |
| Net Income (ttm) | 620.00M |
| Shares Out | 99.94M |
| EPS (ttm) | 6.22 |
| PE Ratio | 26.73 |
| Forward PE | 17.00 |
| Dividend | 4.75 (2.86%) |
| Ex-Dividend Date | Apr 17, 2026 |
| Volume | 172,181 |
| Average Volume | 93,288 |
| Open | 166.00 |
| Previous Close | 166.20 |
| Day's Range | 165.00 - 167.80 |
| 52-Week Range | 159.80 - 212.00 |
| Beta | 0.67 |
| RSI | 38.84 |
| Earnings Date | Apr 29, 2026 |
About Borregaard ASA
Borregaard ASA engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally. It operates in three segments: BioSolutions, BioMaterials, and Fine Chemicals. The BioSolutions segment develops, produces, and sells biopolymers and biovanillin derived from lignin for agrochemicals, batteries, industrial binders, and construction, as well as to flavor and fragrance companies, and food and beverage industry. Its BioMaterials segment develops, ... [Read more]
Financial Performance
In 2025, Borregaard ASA's revenue was 7.71 billion, an increase of 1.26% compared to the previous year's 7.62 billion. Earnings were 620.00 million, a decrease of -24.67%.
Financial StatementsNews
Borregaard ASA: Shares traded ex-dividend today
The shares in Borregaard ASA will be traded ex-dividend of NOK 4.75 per share as from today, 17 April 2026. Borregaard ASASarpsborg, 17 April 2026 Contact: Lotte Kvinlaug, Investor Relations Officer, ...
Borregaard ASA Transcript: AGM 2026
The AGM approved all proposals, including a 12% higher dividend, board and committee elections, and remuneration adjustments. Financial results showed strong growth, with strategic investments in specialization, sustainability, and capacity expansion. No shareholder objections or questions were raised.
Borregaard ASA Transcript: Pre-close call
Sales volumes are set to rise in both BioSolutions and BioMaterials for 2026, though average prices in BioMaterials will decline due to mix and market pressures. Cost volatility, global conflicts, and competition from Chinese imports remain key risks, while currency impacts and hedging strategies are closely monitored.
Borregaard ASA (BRRDF) Q4 2025 Earnings Call Highlights: Record EBITDA Amidst Challenges
Borregaard ASA (BRRDF) Q4 2025 Earnings Call Highlights: Record EBITDA Amidst Challenges
Q4 2025 Borregaard ASA Earnings Call Transcript
Q4 2025 Borregaard ASA Earnings Call Transcript
Borregaard ASA Earnings Call Transcript: Q4 2025
All-time high EBITDA was achieved despite lower bioethanol prices and higher costs, with strong cash flow and improved results in BioSolutions and BioMaterials. The dividend is proposed to increase by 12%, and impairments on bio-based startups and a project delay were recorded.
Borregaard ASA: Key information related to the cash dividend
4 February 2026: Borregaard ASA («Borregaard», OSE ticker: BRG) At a meeting on 3 February 2026, the Board of Directors of Borregaard ASA decided to propose to the Annual General Meeting an ordinary d...
Borregaard ASA: The Board of Directors' dividend proposal to Borregaard's Annual General Meeting
4 February 2026: Borregaard ASA (“Borregaard”, OSE ticker: BRG) At a meeting on 3 February 2026 the Board of Directors of Borregaard ASA decided to propose an ordinary dividend for 2025 of NOK 4.75 pe...
Borregaard ASA: EBITDA1 of NOK 405 million in the 4th quarter 2025
Borregaard's operating revenues increased to NOK 1,833 million (NOK 1,744 million)2 in the 4th quarter of 2025. EBITDA1 was NOK 405 million (NOK 398 million). The result in BioMaterials increased, whi...
Borregaard ASA 4th Quarter 2025 Pre-Close Call Transcript
Borregaard ASA 4th Quarter 2025 Pre-Close Call Transcript
Borregaard ASA Transcript: Pre-Close Call
Q4 outlook reiterates previous guidance, with BioSolutions and BioMaterials volumes slightly down but margins strong. Wood and energy costs are trending favorably, while anti-dumping legal costs and global uncertainties remain key risks.
Borregaard ASA (BRRDF) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
Borregaard ASA (BRRDF) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic Expansions
Q3 2025 Borregaard ASA Earnings Call Transcript
Q3 2025 Borregaard ASA Earnings Call Transcript
Borregaard ASA Earnings Call Transcript: Q3 2025
Q3 2025 EBITDA fell to NOK 440 million, mainly due to lower bioethanol prices and a cellulose production disruption. Biosolutions saw continued agricultural growth, while biomaterials and fine chemicals underperformed. Board approved further Sarpsborg expansion and participated in Alginor financing.
Borregaard ASA: EBITDA1 of NOK 440 million in the 3rd quarter
Borregaard's operating revenues were NOK 1,799 million (NOK 1,949 million)2 in the 3rd quarter of 2025. EBITDA1 was NOK 440 million (NOK 524 million). The result in BioSolutions increased while BioMat...
Borregaard ASA Transcript: Pre-Close Call
Borregaard ASA Earnings Call Transcript: Q2 2025
Q2 2025 saw 5% revenue growth and higher EBITDA, led by biomaterials and BioSolutions, while Fine Chemicals declined. Environmental investments and a strong balance sheet support a positive outlook, with stable or improving margins expected in key segments.
Borregaard ASA Transcript: Pre-Close Call
Sales volumes in BioSolutions and BioMaterials are on track, with agriculture and specialized grades driving growth. Currency hedging and environmental investments support profitability, while tariffs and trade wars introduce uncertainty but are mitigated by diversification and specialization.
Borregaard ASA Earnings Call Transcript: Q1 2025
EBITDA rose to NOK 511 million, driven by record BioSolutions results and strong agricultural sales, while operating revenues surpassed NOK 2 billion. Tariffs and trade tensions pose risks, but a diversified portfolio and environmental investments support resilience.
Borregaard ASA: EBITDA1 of NOK 511 million in the 1st quarter
Borregaard's operating revenues increased to NOK 2,036 million (NOK 1,975 million)2 in the 1st quarter of 2025. EBITDA1 reached NOK 511 million (NOK 442 million). The result in BioSolutions increased,...
Borregaard ASA Transcript: Pre-Close Call
Annual report published with ESRS compliance. 2025 guidance expects stable biosolutions and biomaterials volumes, higher biomaterials prices, and lower bioethanol prices. Wood and energy costs remain key risks, while currency hedging and product mix improvements support profitability.
Q4 2024 Borregaard ASA Earnings Call Transcript
Q4 2024 Borregaard ASA Earnings Call Transcript
Borregaard ASA Earnings Call Transcript: Q4 2024
Q4 and full-year EBITDA reached record highs, led by BioSolutions and specialization, despite higher input costs and lower Fine Chemicals deliveries. Dividend is proposed up 13%, and investments focus on energy efficiency and CO2 reduction. Positive currency effects and stable wood costs are expected in 2025.
Borregaard ASA: EBITDA1 of NOK 398 million in the 4th quarter
Borregaard's operating revenues were NOK 1,744 million (NOK 1,605 million)2 in the 4th quarter of 2024. EBITDA1 reached NOK 398 million (NOK 327 million). The result in BioSolutions increased compared...
Borregaard ASA Earnings Call Transcript: Q3 2024
EBITDA and revenues grew strongly year-over-year, led by higher volumes in Biosolutions and Fine Chemicals. A NOK 490 million capacity expansion at Sarpsborg was announced, and wood costs remain a key risk. Q4 guidance expects stable Biosolutions pricing and lower Fine Chemicals deliveries.